bluuebunny/crossref_metadata_2025_split huggingface dataset:
Late recurrent metastasis in Wilms' tumour
Authors: Gallego‐Melcón Soledad , de Toledo José Sánchez , Doste Divina , López Diana , Moraga Fernando , Rodríguez Carlos , Vidal Teresa , Bellmunt Joaquim 
Published: February 2007

AbstractRecurrence of Wilms' tumour after 5 years of disease‐free survival is rare. We present the case of a 26‐year‐old man who had been diagnosed of Wilms' tumour at the age of 6 years treated by surgery, chemotherapy, and radiotherapy and who remained disease free for 8 years, after which lung metastases were detected. Second complete remission was attained with surgery and chemotherapy and 20 years after initial diagnosis he again presented with lung metastases, similarly achieving complete remission with surgery and secondline chemotherapy.The clinical and biological aspects of late metastasis in this neoplasm are discussed. © 1994 Wiley‐Liss, Inc.
Failure of granulocyte‐macrophage colony‐stimulating factor to reduce febrile neutropenia in children with recurrent solid tumors treated with ifosfamide, carboplatin, and etoposide chemotherapy
Authors: Marina Neyssa M. , Shema Sarah J. , Bowman Laura C. , Rodman John , Douglass Edwin C. , Furman Wayne L. , Pappo Alberto , Santana Victor M. , Hudson Melissa , Meyer William H. , Pratt Charles B. 
Published: February 2007

AbstractIfosfamide, carboplatin, and etoposide (ICE) chemotherapy has promising activity against various solid tumors but produces significant myelotoxicity that might be ameliorated by hematopoietic growth factors. Twelve patients with relapsed solid tumors were treated with ICE chemotherapy. Carboplatin was given on day 1 at a targeted area under the concentration‐time curve (AUC) of 8 mg/mL × min (adjusted for each patient's glomerular filtration rate), followed by ifosfamide 2 g/m2 and etoposide 100 mg/m2 on days 2 through 4. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), 1,000 μg/m2/day, was started 24 hours after each course and given for 17 days or until the absolute neutrophil count (ANC) reached 10 × 109/L. Myelotoxicity and responses in these patients were compared to those of eight patients who received the same therapy without GM‐CSF. Patients received a median of three courses (range, 1–8). All 20 patients developed grade 4 neutropenia and grade 3 or 4 thrombocytopenia. The median duration of neutropenia was significantly shorter in patients who received GM‐CSF (16.75 vs. 10 days, P = 0.005). However, the two groups did not differ in the proportion of courses associated with hospitalization for febrile neutropenia, the duration of hospitalization, or the median duration of thrombocytopenia. There were two complete, four partial, and three objective responses in the 12 patients treated with ICE plus GM‐CSF, and two partial and three objective responses in the 8 patients treated with ICE only. GM‐CSF did not reduce the occurrence of febrile neutropenia or the duration of thrombocytopenia associated with ICE chemotherapy. Studies of other hematopoietic growth factors in conjunction with this promising combination are merited. © 1994 Wiley‐Liss, Inc.
Secondary breast cancer in patients presenting with osteosarcoma: Possible involvement of germline p53 mutations
Authors: Russo Carolyn L. , McIntyre James , Goorin Allen M. , Link Michael P. , Gebhardt Mark C. , Friend Stephen H. 
Published: February 2007

AbstractSecond malignancies following treatment for osteosarcoma are unusual. Breast cancer occurring in patients with osteosarcoma has been reported following therapeutic chest irradiation. We now report three cases of breast cancer occurring in young women who were successfully treated for osteosarcoma. These women had not received therapeutic chest irradiation and in two of the three women there was no family history of breast cancer. Peripheral blood was available for study from one case. Of import, this case demonstrated a germline mutation in exon 7 of the tumor suppressor gene, p53. The mutation was detected by constant denaturing gradient gel electrophoresis and confirmed by DNA sequencing. In this particular patient, inactivation of the p53 gene may be involved in the development of both the first and second malignancy. © 1994 Wiley‐Liss, Inc.
Primary intraspinal soft‐tissue sarcoma in childhood: Report of two cases with a review of the literature
Authors: Raney R. Beverly , Ater Joann L. , Herman‐Liu Alisa , Leeds Norman E. , Cleary Karen R. , Womer Richard B. , Rorke Lucy M. 
Published: February 2007

AbstractTwo young children who presented with lower spinal cord dysfunction manifested by bilateral leg weakness and urinary retention were diagnosed with intraspinal soft‐tissue sarcoma. Neither patient had a significant extradural mass. Both tumors had histochemical features of rhabdomyosarcoma. Temporary responses were noted after combination chemotherapy either with vincristine, actinomycin D, and cyclophosphamide or with ifosfamide/mesna and etoposide. However, both patients developed uncontrollable cerebrospinal fluid (CSF) dissemination of tumor and died within 6 months of diagnosis, despite intrathecal chemotherapy and irradiation for one and very high‐dose intravenous methotrexate (33 g/m2) for the other. This rare tumor can respond to parenteral antisarcoma chemotherapy, but better strategies are needed to prevent CSF spread and ultimate demise. Early institution of intrathecal cytostatic agents may retard or prevent CSF dissemination and prolong survival. © 1994 Wiley‐Liss, Inc.
Benign hematologic neoplasm associated with mediastinal mature teratoma in a patient with Klinefelter's syndrome: A case report
Authors: Zon Robin , Orazi Attilio , Neiman Richard S. , Nichols Craig R. 
Published: February 2007

AbstractAn 18‐year‐old male with Klinefelter's syndrome presented with a mature teratoma of the mediastinum. He was treated with de‐bulking surgery and brief cisplatin‐based chemotherapy. Ten years later, he presented with paraplegia and was found to have an isolated epidural mass. The mass was composed of mature histiocytoid cells reminiscent of those seen in malignant histio‐cytosis. There was no evidence of medullary dissemination and there was no evidence of recurrence of the germ cell tumor. He received local radiation therapy and a single course of leukemic induction. He remains well 4 years later. This case represents a localized variant of the diffuse histiocytic malignancies associated with malignant mediastinal germ cell tumors. © 1994 Wiley‐Liss, Inc.
Malignant peripheral primitive neuroectodermal tumor (PNET) of the kidney
Authors: Mor Yoram , Nass Dvora , Raviv Gil , Neumann Yoram , Nativ Ofer , Goldwasser Benad 
Published: February 2007

AbstractWe describe a 61‐year‐old patient with primitive neuroectodermal tumor (PNET) arising from the kidney. Despite intensive treatment including surgery, combination chemotherapy and radiotherapy, rapid progression of the tumor was encountered and the patient died within six months with widespread disease. This appears to be the first recorded case of PNET of the kidney. © 1994 Wiley‐Liss, Inc.
Ependymoblastoma in an HIV‐positive hemophilic girl
Authors: Mandel Mathilda , Toren Amos , Hadani Moshe , Engelberg Isaac , Martinowitz Uri , Rechavi Gideon 
Published: February 2007

AbstractA case of an HIV‐positive hemophilic girl with an ependymoblastoma is presented. The unusual association between the HIV‐related condition and her brain tumor is discussed, speculating a viral mechanism involved in the induction of neoplasia. © 1994 Wiley‐Liss, Inc.
Monocyte/macrophage system and malignancies
Authors: Schmidt Dietmar 
Published: February 2007

AbstractNeoplasias of the monocyte/macrophage system are rare. They include malignant histocytosis, sarcomas of dendritic cells, and possibly a malignant form of Langerhans cell histiocytosis. Characterization of all these neoplasms can be easily done along the lines which have been developed for the derivation of the normal cellular counterparts. The possibility of a malignant transformation of the cells of the monocyte/macrophage system is suggested by the fact that all members of this system can undergo mitotic division. The most controversial among the different entities is malignant histiocytosis, which has proved to be anaplastic large cell lymphoma (ALCL) with Ki1 expression in most cases. The few cases of true malignant histocytosis may or may not express the Ki1 antigen. Sarcomas of dendritic cells have been related mainly to interdigitating or follicular dendritic cells. Prognosis of follicular dendritic cell sarcoma is probably more favorable than that of interdigitating cell sarcoma. Besides these more frequent subtypes, a sarcoma of the sinus lining cells can be separated which represents a low‐grade malignant neoplasm. All cases encountered so far were associated with a protracted clinical course, albeit multiple recurrences. A distinctly more aggressive behavior is encountered in those cases which have been identified as a malignant form of Langerhans cell histiocytosis. However, the issue of this particular form of histiocytic disorder is still unsettled. © 1994 Wiley‐Liss, Inc.
Osteosarcoma of the trunk treated by multimodal therapy: Experience of the cooperative osteosarcoma study group (COSS)
Authors: Bielack Stefan S. , Wulff Beate , Delling Günther , Göbel Ulrich , Kotz Rainer , Ritter Jörg , Winkler Kurt 
Published: February 2007

AbstractThe case histories of all patients with osteosarcoma of the trunk entered into the consecutive studies COSS 80 through COSS 86 of the Cooperative German/Austrian Osteosarcoma Study Group (COSS) were analyzed in order to evaluate their clinical characteristics and the impact of modern neoadjuvant therapy on prognosis. They were compared to those of all patients with extremity osteosarcoma treated according to the same protocols. While tumors of the trunk comprised only 32 (4.8%) of 665 primary classical osteosarcomas, secondary osteosarcomas were much more likely to be located in bones of the axial skeleton (6 of 18, 33%). Patients with primary osteosarcoma of the axial skeleton were older (mean: 20.8 vs. 15.2 years,P< 0.01) and were more likely to present with metastases at diagnosis (34% vs 12%,P< 0.001) than those with primary extremity osteosarcoma.In contrast to extremity tumors, local surgical treatment failure was very common in osteosarcomas of the trunk. Complete tumor removal was achieved in less than half of all evaluable cases. The prognosis of eight patients with localized primary axial osteosarcoma and effective surgical local control was not inferior to that of 483 equally evaluable patients with extremity tumors.In conclusion, while secondary systemic spread of axial osteosarcoma may be avoided in patients treated with multiagent chemotherapy, successful treatment is often barred by primary metastatic disease and inability to control the local tumor site. © 1995 Wiley‐Liss, Inc.
Primary thyroid carcinoma in children: A retrospective study of 20 patients
Authors: Massimino Maura , Gasparini Marco , Ballerini Emanuela , Del Bo Romualdo 
Published: February 2007

AbstractA total of 20 children (median age 11 years) were treated for primary thyroid carcinoma from 1976 to 1990. Papillary adenocarcinoma was diagnosed in 19 and follicular in one case. Nineteen of 20 patients were considered amenable to surgery, which consisted of total thyroidectomy in 14 and partial thyroidectomy in 5. Only one patient with extensive perithyroid soft tissue infiltration was treated with external beam radiotherapy. Monolateral or bilateral cervical nodal dissection was performed in eight and six children, respectively; in nine cases without clinical evidence of metastatic nodes. Pathological examination showed that tumor extent was greater than that clinically assessed: Multiple tumor foci within the thyroid were assessed in 8/19, unilateral positive nodes in 8, and bilateral in 6, and soft tissue infiltration in 7. Subsequently 10 patients received thyroid‐stimulating hormone (TSH) suppressive hormonotherapy. Relapses occurred in 7/20 at 2–48 months (median 18) from primary treatment: Four in cervical nodes, two in cervical nodes and lungs, and one in lungs. These seven patients were salvaged with node dissection and radioiodine therapy for lung metastases. All the 20 children are alive and disease‐free after a median follow‐up of longer than 10 years. The incidence of relapse was greater in the group of patients not given TSH‐suppressive hormonotherapy. Total thyroidectomy produced permanent hypoparathyroidism in 5/14 (36%). Thyroid carcinoma in children of this series frequently presented with multiple tumor foci within the thyroid and cervical node metastases. Prognosis was favourable even after relapse and was not related to the extent of surgical treatment. Limited surgery and suppressive hormonotherapy may be adequate therapy for thyroid carcinoma in children. © 1995 Wiley‐Liss, Inc.
Induction toxicity in childhood acute lymphoblastic leukemia: A comparison of two schedules of daunorubicin administration
Authors: Shaw Peter J. , Eden Tim , Paradisis Mary 
Published: February 2007

AbstractThe haematological toxicity of the induction phase of chemotherapy for acute lymphoblastic leukaemia (ALL) was compared in two cohorts of patients. The principal difference between these two cohorts was the mode of administration of the anthracycline, daunorubicin (DNR). Both groups received four‐drug induction chemotherapy, which produced a high remission rate. Those receiving DNR on days 1 and 2 experienced a profound but shorter period of neutropenia and more severe thrombocytopenia than those who received the DNR weekly. The pattern of hospitalisation and support facilities in the individual unit may determine which regimen is to be preferred. These observations are relevant for the newly diagnosed patient in whom an anthracycline is retained in the induction therapy for ALL. © 1995 Wiley‐Liss, Inc.
Treatment of stage III neuroblastoma with emphasis on intensive induction chemotherapy: A report from the neuroblastoma group of the spanish society of pediatric oncology
Authors: Castel V. , Badal M. D. , Bezanilla J. L. , Llombart A. , Ruiz‐Jiménez J. I. , De Toledo J. Sánchez , Melero C. , Mulet J. 
Published: February 2007

AbstractFrom October 87 to April 92, 172 children were admitted in the N‐I‐87 protocol of the Spanish Society of Pediatric Oncology for the diagnosis and treatment of neuroblastoma. Forty‐eight were considered Evans stage III, 33 of them being older than 1 year. All children were treated with induction chemotherapy (IC) and surgery. IC consisted of three courses of high‐dose cisplatin‐VM‐26 alternating with three further courses of cyclophosphamide‐doxorubicin (CAD). Infants less than 1 year received the same drugs at lower doses.After surgery, maintenance chemotherapy was administered to all children during 14 months. It consisted of four pairs of drugs rotated every 4 weeks. Radiotherapy was administered exclusively to patients older than 1 year with residual tumor after IC and surgery.Response was evaluated after IC and surgery. In children older than 1 year, response was obtained in 28/33 (88%). Fifteen of them (47%) achieved complete remission (CR), seven (22%) good partial response (GPR), six (19%) partial response (PR); and in three patients (9%) there was progressive disease (PD). Actuarial survival at 48 months was 0.60 ± 0.10 and EFS was 0.61 ± 0.12. Audiologic impairment was considered the worst toxicity. In children less than 1 year the response rate to IC and surgery was 93% (14/15); nine infants obtained complete response and four had GPR. Only one patient experienced PD in the first 6 months of therapy and died. The other 14 are alive and well at a mean follow‐up time of 48 months. Chemotherapy toxicity was mild and reversible. © 1995 Wiley‐Liss, Inc.
Streptococcus sanguis bacteremia and colorectal cancer: A case report
Authors: Kampe Carsten E. , Vovan Thomas , Alim Awoni , Berenson James 
Published: February 2007

AbstractStreptococcus sanguis, usually considered a nonpathogen of the oral cavity, was isolated from blood cultures from a patient who was subsequently found to have a cecal adenocarcinoma. Further studies are needed to determine if Streptococcus sanguis infections have diagnostic implications similar to those of Streptococcus bovis. © 1995 Wiley‐Liss, Inc.
Relapse after first cessation of therapy in childhood acute lymphoblastic leukemia: A 10‐year follow‐up study
Authors: Miniero R. , Saracco P. , Pastore G. , Zurlo M. G. , Terracini B. , Rosso P. , Masera G. 
Published: February 2007

AbstractThe outcome of 171 children with ALL who relapsed for the first time after elective cessation of therapy (1–86 mo) and followed over 10 years (median 60 mo; range 1–232 mo) has been evaluated. One hundred and three patients relapsed in the bone marrow (BM), 29 in the testis (T), 21 in the central nervous system (CNS), 14 in the BM plus another site and 4 in other sites. Second remission was achieved in 97% of patients (97% BM, 100% T, 90% CNS, respectively) with reinduction schedules including three or more drugs. All but 4 out of 100 patients who relapsed in the BM received cranial reprophylaxis with intrathecal CT alone or CT plus radiotherapy. Seven patients in second CR underwent allogeneic bone marrow transplantation from an HLA matched sibling. The overall survival was 34% and disease‐free survival (DFS) probability at 100 years was 22%. A second relapse was observed in 73% of patients. Forty children are alive in second continuous remission and 24 are alive after a second or subsequent relapse. Patients with isolated T relapse showed a significant better outcome than those with BM or CNS involvement. Most patients (62%) with isolated BM relapse showed a further disease recurrence in BM, and DFS was shorter when relapse occurred within 12 months from off‐therapy. Eighty‐two patients in second CR stopped the treatment a second time and showed a survival and DFS probabilities, respectively, of 69% and 43%.Thus, children with ALL who relapse after cessation of therapy still have a high risk of further late relapses and should be treated with intensive chemotherapy and CNS reprophylaxis. BMT must be considered for all patients relapsing in the BM within 12 months from off‐therapy. © 1995 Wiley‐Liss, Inc.
Increased renal parenchymal echogenicity in ifosfamide‐induced renal fanconi syndrome
Authors: Hanquinet Sylviane , Wouters Michael , Devalck Christine , Perlmutter Noemie , Sariban Eric 
Published: February 2007

AbstractThree children who presented with a Fanconi syndrome induced by the chemotherapeutic drug ifosfamide were found to have renal abnormalities on sonogram examinations. Renal echographic changes consisted in hyperechogenicity of the parenchyma with good corticomedullar differentiation. After discontinuation of the chemotherapy, the serum and urine metabolic abnormalities due to proximal tubulopathy were completely or greatly improved. Imaging studies at that time showed a complete resolution of the renal hyperechogenicity. We suggest that in patients exposed to ifosfamide, renal sonogram may be of value to monitor the tubular toxicity of this drug. In these patients, urine and serum monitoring as well as prospective echographic follow‐up kidney abnormalities may lead to earlier detection of ifosfamide‐induced Fanconi syndrome as well as earlier detection of disease reversibility. © 1995 Wiley‐Liss, Inc.
Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD, or MBVD
Authors: Avilés Agustin , Soto Bibiana , Guzmán Renaldo , García Edna L. , Nambo M. Jesús , Díaz‐Maqueo José C. 
Published: February 2007

AbstractFrom January 1986 to December 1989, 157 previously untreated patients, with Hodgkin's disease stage I or II without bulky disease, were enrolled in a clinical comparative study. The objectives of the study were to compare the efficacy and safety of using epirubicine or mitoxantrone instead of adriamycin in the combination chemotherapy regimen ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine). The complete response rate was better in the patients treated with the ABVD or EBVD regimens compared to the MBVD arm. Also, differences in overall survival and relapse‐free survival were better in the patients who received ABVD or EBVD compared to the MBVD regimen.Hematological, gastrointestinal and cardiac toxicity were similar in the three groups. Dose intensity, delays and complications were also similar in the three groups. The mitoxantrone‐containing regimen was found to have less efficacy in comparison to the other regimens tested in the present study in patients with favorable stage I or II Hodgkin's disease. © 1995 Wi1ey‐Liss Inc.
Cyclophosphamide/doxorubicin vs. Cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: A pediatric oncology group randomized phase II study
Authors: McWilliams Nancy B. , Hayes F. Ann , Green A. A. , Smith E. Ide , Nitschke Ruprecht , Altshuler Geoffrey A. , Shuster Jonathan J. , Castleberry Robert P. , Vietti Teresa J. 
Published: February 2007

AbstractThis prospective study was designed to estimate the response rates and to compare two drug pairs, cyclophosphamide/doxorubicin (Cy/A) and cisplatin/teniposide (P1/VM) in previously untreated patients with disseminated neuroblastoma >12 months of age at diagnosis. Estimated complete clinical response rates after five courses of therapy were 13% (70 patients) and 22% (64 patients) for Cy/A and P1/VM, respectively (P = 0.17). After surgical removal of residual tumors in patients with partial response, the complete response rates were 27% and 34% (P = 0.50), respectively. The overall CR/PR rates after induction and surgery were 59% and 73% (P = 0.077). There was no significant difference in event free survival (P = 0.48) or survival (P = 0.40). Five year survival on the two arms were 14% (SE = 5%) and 12% (SE = 4%), respectively. Toxicity was significant but manageable. The Cy/A arm had significantly higher hematopoietic toxicity but significantly lower GI toxicity. Significant allergic reactions were seen with the P1/VM arm, none in the Cy/A arm. Given the activity of these two regimens, further therapy with a combination of these regimens is suggested. © 1995 Wiley‐Liss, Inc.